Propanc Biopharma, Inc. financial data

Symbol
PPCB on OTC
Industry
Pharmaceutical Preparations
Location
302/6 Butler Street, Camberwell, Victoria, Australia
State of incorporation
DE
Fiscal year end
June 30
Former names
Propanc Health Group Corp (to 4/5/2017)
Latest financial report
10-K - Q2 2024 - Sep 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.75 % +59.1%
Debt-to-equity -104 % -0.32%
Return On Equity 51.9 % -42.7%
Return On Assets -1.37K % +47.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 688M shares +4538%
Common Stock, Shares, Outstanding 479M shares +7839%
Entity Public Float 425K USD -42.5%
Common Stock, Value, Issued 479K USD +7839%
Weighted Average Number of Shares Outstanding, Basic 85M shares +4791%
Weighted Average Number of Shares Outstanding, Diluted 85M shares +4791%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 248K USD +0.07%
General and Administrative Expense 1.25M USD -16.4%
Operating Income (Loss) -1.54M USD +13.5%
Nonoperating Income (Expense) -414K USD +59.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.95M USD +30.1%
Income Tax Expense (Benefit) -275 USD +84%
Net Income (Loss) Attributable to Parent -1.82M USD +31.6%
Earnings Per Share, Basic -0.02 USD/shares +98.9%
Earnings Per Share, Diluted -0.02 USD/shares +98.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.2K USD -30.4%
Assets, Current 25.4K USD +33.6%
Property, Plant and Equipment, Net 50 USD -95.4%
Operating Lease, Right-of-Use Asset 44.5K USD
Assets 72.4K USD +20%
Accounts Payable, Current 1.21M USD +25.5%
Employee-related Liabilities, Current 639K USD +8.81%
Liabilities, Current 3.79M USD +20.1%
Operating Lease, Liability, Noncurrent 24.9K USD
Liabilities 3.85M USD +21.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.27M USD -1.95%
Retained Earnings (Accumulated Deficit) -66.7M USD -3.11%
Stockholders' Equity Attributable to Parent -3.78M USD -21.2%
Liabilities and Equity 72.4K USD +20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -333K USD +34.5%
Net Cash Provided by (Used in) Financing Activities 350K USD -29.1%
Common Stock, Shares Authorized 10B shares 0%
Common Stock, Shares, Issued 479M shares +7839%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.42K USD -122%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.71K USD +19.1%
Deferred Tax Assets, Valuation Allowance 11.5M USD +2.75%
Deferred Tax Assets, Gross 12.1M USD +2.51%
Depreciation 297 USD -82.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.04M USD +33.5%
Lessee, Operating Lease, Liability, to be Paid 19.4K USD -52.5%
Property, Plant and Equipment, Gross 25.5K USD +0.44%
Operating Lease, Liability, Current 21.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 20.1K USD -16.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78K USD -65.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 19.3K USD
Deferred Tax Assets, Operating Loss Carryforwards 9.08M USD +1.84%
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 61.2M USD +1.5%
Preferred Stock, Shares Outstanding 1.5M shares
Deferred Tax Assets, Net of Valuation Allowance 11.5M USD +2.75%
Share-based Payment Arrangement, Expense 0 USD -100%
Interest Expense 690K USD +29.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%